Answers are grounded in this paper and cite their sources.
Podocalyxin (PODXL) is a potential diagnostic biomarker and therapeutic target in various tumors. Development of anti-PODXL mAbs has been limited by concerns about potential reactivity with normal tissues. To minimize on-target, off-tumor toxicities and adverse effects, we developed cancer-specific mAbs (CasMabs) against PODXL and demonstrated antitumor efficacy in human tumor xenograft models. In this study, we evaluated humPcMab-60-DXd, an anti-PODXL CasMab conjugated with DXd, a derivative of the topoisomerase I inhibitor exatecan. humPcMab-60-DXd retained cancer-specific reactivity with the pancreatic ductal adenocarcinoma MIA PaCa-2 cell line. Furthermore, humPcMab-60 was internalized into MIA PaCa-2 and inhibited cell proliferation in vitro. In the MIA PaCa-2 xenograft model, humPcMab-60-DXd showed superior antitumor efficacy compared with humPcMab-60. Moreover, humPcMab-60-DXd exhibited dose-dependent antitumor activity without reducing mice body weight. Histological analyses revealed the collapse of the intratumoral structure and a reduction in PODXL expression in the humPcMab-60-DXd-treated xenograft. These results provide the first observation of antitumor efficacy for an anti-PODXL CasMab–drug conjugate, which could facilitate the clinical development of CasMabs for tumor therapy.
No takes yet. Share an insight, caveat, or question.
Nakamura et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: